Class information for: |
Basic class information |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | ONCOLOGY//CELL BIOLOGY//BIOCHEMISTRY & MOLECULAR BIOLOGY | 2934640 |
236 | 3 | PROSTATE CANCER//PROSTATIC NEOPLASMS//UROL | 47933 |
282 | 2 | PROSTATE CANCER//PROSTATE//ANDROGEN RECEPTOR | 19095 |
1640 | 1 | ANDROGEN DEPRIVATION THERAPY//BICALUTAMIDE//INTERMITTENT ANDROGEN SUPPRESSION | 2580 |
Terms with highest relevance score |
rank | Category | termType | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|---|
1 | ANDROGEN DEPRIVATION THERAPY | authKW | 1153784 | 10% | 37% | 257 |
2 | BICALUTAMIDE | authKW | 525889 | 4% | 41% | 105 |
3 | INTERMITTENT ANDROGEN SUPPRESSION | authKW | 403409 | 1% | 97% | 34 |
4 | COMBINED ANDROGEN BLOCKADE | authKW | 402669 | 2% | 70% | 47 |
5 | DEGARELIX | authKW | 371533 | 2% | 78% | 39 |
6 | ANDROGEN ANTAGONISTS | authKW | 350311 | 2% | 46% | 62 |
7 | PROSTATE CANCER | authKW | 259420 | 30% | 3% | 773 |
8 | LHRH AGONIST | authKW | 250085 | 2% | 40% | 51 |
9 | ANTIANDROGEN | authKW | 236619 | 4% | 17% | 112 |
10 | ANDROGEN DEPRIVATION | authKW | 235571 | 3% | 24% | 81 |
Web of Science journal categories |
chi_square_rank | Category | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | Urology & Nephrology | 87769 | 53% | 1% | 1376 |
2 | Oncology | 5826 | 26% | 0% | 668 |
3 | Endocrinology & Metabolism | 1887 | 11% | 0% | 295 |
4 | Andrology | 1394 | 2% | 0% | 39 |
5 | Medicine, General & Internal | 161 | 5% | 0% | 139 |
6 | Pharmacology & Pharmacy | 140 | 7% | 0% | 181 |
7 | Geriatrics & Gerontology | 21 | 1% | 0% | 20 |
8 | Health Care Sciences & Services | 15 | 1% | 0% | 25 |
9 | Nursing | 6 | 1% | 0% | 16 |
10 | Primary Health Care | 2 | 0% | 0% | 5 |
Address terms |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | UROL | 59585 | 29% | 1% | 752 |
2 | STRATEG INVEST COMPREHENS CANC NETWORK | 35909 | 0% | 29% | 10 |
3 | WARD 14 | 27480 | 0% | 75% | 3 |
4 | INTEGRAT CANC THER Y UROL | 21363 | 1% | 10% | 17 |
5 | UROEVIDENCE | 18318 | 0% | 50% | 3 |
6 | J ANESE UROL ASSOC | 16284 | 0% | 67% | 2 |
7 | AKKREDITIERTES ZWEITMEINUNGSZENTRUM KEIMZELLTUMOR | 12214 | 0% | 100% | 1 |
8 | AMER FDN UROL DIS PROSTATE QUAL ENHANCEMENT | 12214 | 0% | 100% | 1 |
9 | ASHLAND COMMUNITY HOSP | 12214 | 0% | 100% | 1 |
10 | ASTRADRACO RD | 12214 | 0% | 100% | 1 |
Journals |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
---|---|---|---|---|---|
1 | PROSTATE CANCER AND PROSTATIC DISEASES | 48309 | 3% | 6% | 67 |
2 | EUROPEAN UROLOGY SUPPLEMENTS | 45566 | 2% | 8% | 47 |
3 | EUROPEAN UROLOGY | 45336 | 6% | 2% | 165 |
4 | UROLOGY | 26960 | 7% | 1% | 192 |
5 | BJU INTERNATIONAL | 21982 | 5% | 1% | 122 |
6 | PROSTATE | 21229 | 3% | 2% | 90 |
7 | JOURNAL OF UROLOGY | 15754 | 7% | 1% | 191 |
8 | MOLECULAR UROLOGY | 8425 | 0% | 6% | 11 |
9 | BRITISH JOURNAL OF UROLOGY | 7977 | 2% | 1% | 63 |
10 | PROGRES EN UROLOGIE | 6074 | 2% | 1% | 41 |
Author Key Words |
chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass | LCSH search | Wikipedia search |
---|---|---|---|---|---|---|---|
1 | ANDROGEN DEPRIVATION THERAPY | 1153784 | 10% | 37% | 257 | Search ANDROGEN+DEPRIVATION+THERAPY | Search ANDROGEN+DEPRIVATION+THERAPY |
2 | BICALUTAMIDE | 525889 | 4% | 41% | 105 | Search BICALUTAMIDE | Search BICALUTAMIDE |
3 | INTERMITTENT ANDROGEN SUPPRESSION | 403409 | 1% | 97% | 34 | Search INTERMITTENT+ANDROGEN+SUPPRESSION | Search INTERMITTENT+ANDROGEN+SUPPRESSION |
4 | COMBINED ANDROGEN BLOCKADE | 402669 | 2% | 70% | 47 | Search COMBINED+ANDROGEN+BLOCKADE | Search COMBINED+ANDROGEN+BLOCKADE |
5 | DEGARELIX | 371533 | 2% | 78% | 39 | Search DEGARELIX | Search DEGARELIX |
6 | ANDROGEN ANTAGONISTS | 350311 | 2% | 46% | 62 | Search ANDROGEN+ANTAGONISTS | Search ANDROGEN+ANTAGONISTS |
7 | PROSTATE CANCER | 259420 | 30% | 3% | 773 | Search PROSTATE+CANCER | Search PROSTATE+CANCER |
8 | LHRH AGONIST | 250085 | 2% | 40% | 51 | Search LHRH+AGONIST | Search LHRH+AGONIST |
9 | ANTIANDROGEN | 236619 | 4% | 17% | 112 | Search ANTIANDROGEN | Search ANTIANDROGEN |
10 | ANDROGEN DEPRIVATION | 235571 | 3% | 24% | 81 | Search ANDROGEN+DEPRIVATION | Search ANDROGEN+DEPRIVATION |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Classes with closest relation at Level 1 |